Insights into COVID-19’s aftermath: 2-year study examines lasting health effects

Researchers comprehensively assessed the risks and burdens of post-acute sequelae of coronavirus disease 2019.

ZNA-1041 by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

February 16, 2024

Bessemer VC Morgan Cheatham shares how AI healthcare startups can win in a crowded market

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Among what seems like … Sign up

July 30, 2024

Early understanding of diabetes risk could help in better disease management

With diabetes increasing at an alarming rate in the United States, Diabetes Alert Day is meant to be a one-day “wake-up call” to the seriousness

March 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.